Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...
Adding Inhibrx Biosciences’ OX40 agonist to Keytruda doubled the response rate in a midphase clinical trial, encouraging the ...
Seven months after Novo Nordisk abandoned its push into cell therapy, the pharma’s Parkinson’s disease program looks like ...
Q1 2026 net revenue growth year-over year for Acute Care franchise (+32%), including ZYNRELEF® (+27%) and APONVIE® (+50%)Q1 ...
Sino Biological Europe GmbH, the regional subsidiary of global life science reagent and service provider Sino Biological, has recently launched ...
Cameron Sheeler, Ph.D., dressed in character for an episode on Western blots, and Kevin Storr in Sheeler's lab. Learning the ...
Sara Ahmed ’26, a student in the MBA for Executives program, drew on her background in biotech to craft a speaker series ...
Summit Therapeutics' closely watched PD-1xVEGF study surprisingly missed its mark at an interim analysis. | Summit's ...
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today reported ...
Private biotech firm Partner Therapeutics said on Wednesday the U.S. Food and Drug Administration has granted a priority ...
Bioversity, which spun out of MassBio in 2023, opened its first training center in Boston’s Dorchester neighborhood in ...
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales up 32% YoY to $116.4M and gross margin expanding to 95%.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results